{
  "first_published_at": "2012-06-22", 
  "original_url": "http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON155756", 
  "title": "Oral tacrolimus products: prescribe and dispense by brand name only, to minimise the risk of inadvertent switching between products, which has been associated with reports of toxicity and graft rejection", 
  "tags": "{\"parsed_therapeutic\": [\"immunosuppression-transplantation\"], \"Audience:\": [\"Primary care\", \"Secondary care\"], \"Therapeutic area:\": [\"Immunosuppression and transplantation\"]}", 
  "_document_number": 112, 
  "label": null, 
  "icon": "http://www.mhra.gov.uk/home/images/MHRALook/img/dsu/dose_icon.png", 
  "therapeutic_area": [
    "immunosuppression-transplantation"
  ], 
  "raw_html": "<div id=\"dsuArticleContent\">\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\t<h1><a name=\"maincontent\" id=\"maincontent\"></a>Oral tacrolimus products: prescribe and dispense by brand name only, to minimise the risk of inadvertent switching between products, which has been associated with reports of toxicity and graft rejection</h1>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<span class=\"ref\">Article date: June 2012</span> \r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t<!---->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<div id=\"dsuSynopsis\" class=\"yellow\">\r\n\t\t\t\t\t\t\t\t\t<div class=\"dsuArticlePadding\">\r\n\t\t\t\t\t\t\t\t\t<span id=\"dsuSynopsisTitle\"><b>Summary</b></span>\t\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\t<br>The growing number of oral tacrolimus products available on the market increases the potential for inadvertent switching between products, which has been associated with reports of toxicity and graft rejection. Therefore, to ensure maintenance of therapeutic response when a patient is stabilised on a particular brand, oral tacrolimus products should be prescribed and dispensed by brand name only.<br>\n<br>\nIf a prescriber considers that switching a patient to a different brand of oral tacrolimus would be of benefit, the change requires careful supervision and therapeutic monitoring by an appropriate specialist<br>\t\r\n\t\t\t\t\t\t\t\t\t</div>         \t\t\r\n\t\t\t\t\t\t\t\t\t<div id=\"dsuSynopsisCut\">\r\n\t\t\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t<!--<p>Tacrolimus is an immunosuppressant drug which may be given orally to prevent or treat organ transplant rejection. Tacrolimus has a narrow therapeutic index, and even minor differences in blood levels have the potential to cause graft rejection reactions</p>\n\n<h3>Oral tacrolimus and inadvertent switching between products</h3>\n\n<p>Since 2008, the MHRA has been aware of reports of unintended switching between different pharmaceutical forms of oral tacrolimus products in patients who have been treated with tacrolimus for the prevention of organ transplant rejection. Graft rejection reactions and tacrolimus toxicity have resulted from a small number of these unintended switches between products.</p>\n\n<h3>Prescribing oral tacrolimus products</h3>\n\n<p>As there are a growing number of tacrolimus products available on the UK market, the Commission on Human Medicines CHM has now advised that the risk of inadvertent switching between the different products may increase.</p>\n\n<p>Therefore, as a precautionary measure, the CHM has updated its advice on the safer use of oral tacrolimus products and recommends that <strong>all oral tacrolimus products should be prescribed and dispensed by brand name only</strong>. This supersedes previous advice regarding the prescribing, dispensing and interchangeability of different tacrolimus products (see Drug Safety Update January 2009, February 2010, and May 2010).</p>\n\n<p>A <a target=\"_blank\" href=\"https://www.cas.dh.gov.uk/ViewandAcknowledgment/ViewAlert.aspx?AlertID=101781\">letter on the updated advice for oral tacrolimus products</a> was sent to healthcare professionals in May 2012. The purpose of the new advice is to ensure maintenance of therapeutic response when a patient is stabilised on a particular brand, and to minimise the risk of inadvertent switching between products from different suppliers. As all tacrolimus products are approved in the UK with a brand name, the easiest way to achieve this is to prescribe by brand name only.</p>\n\n<p><strong>Important: careful therapeutic monitoring is recommended for any switching between tacrolimus brands. The currently available brands of oral tacrolimus are:</strong></p>\n\n<ul>\n<li>Immediate-release capsule taken twice daily (including Adoport, Aletris, Capexion, Evenil, Miloprosan, Prograf, Tacni, Takon, Taliximun, Tamitect and Vivadex)</li>\n\n<li>Prolonged-release capsule taken once daily (Advagraf)</li>\n\n<li>Granules for oral solution taken twice daily (Modigraf)</li>\n</ul>\n\n<p>If the exact brand of tacrolimus is not clearly stated on the prescription, the dispensing pharmacist should check with the prescriber to ensure that the appropriate medicine is dispensed.</p>\n\n<h3>Changing oral tacrolimus products</h3>\n\n<p>This updated recommendation does not preclude patients changing to a different tacrolimus brand if the prescriber considers this to be of benefit to the patient. However, changes between different brands (which may or may not involve changes in dosing regimen), should always be accompanied by careful therapeutic monitoring under the supervision of an appropriate specialist.</p>\n\n<div class=\"dull_highlight\">\n<p><strong>Advice for healthcare professionals and patients:</strong></p>\n\n<ul>\n<li>Prescribers should prescribe oral tacrolimus products by brand name only. When prescriptions have been previously written using the generic name, the brand on which the patient is stabilised should be established to ensure that the patient is supplied with the same product</li>\n</ul>\n\n<ul>\n<li>If a prescriber intends to switch between any tacrolimus brand, careful medical supervision and therapeutic monitoring are required</li>\n</ul>\n\n<ul>\n<li>Pharmacists should always dispense the exact brand prescribed. They should contact the prescriber if the prescription is not clear to ensure the appropriate medicine is dispensed</li>\n</ul>\n\n<ul>\n<li>Patients should be advised to take careful note of the brand name of their usual tacrolimus medicine and should check with their doctor or pharmacist if they receive a different brand or if they have any other questions about the prescription, eg about the dose</li>\n</ul>\n</div>\n\n<p><strong>Further information:</strong></p>\n\n<p><a target=\"_blank\" href=\"https://www.cas.dh.gov.uk/ViewandAcknowledgment/ViewAlert.aspx?AlertID=101781\">Letter to healthcare professionals on updated advice for oral tacrolimus products</a></p>\n\n<p><a target=\"_blank\" href=\"http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/CON152758\">MHRA information webpage on prescribing and dispensing oral tacrolimus products</a></p>\n\n<p>BNF section 8.2 <a target=\"_blank\" href=\"http://www.medicinescomplete.com/mc/bnf/current/27585.htm\">Drugs affecting the immune response</a></p>\n\n<p><em>Article citation: Drug Safety Update June 2012, vol 5 issue 11: A1</em></p>-->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_BEGIN_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t\t<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t<p>Tacrolimus is an immunosuppressant drug which may be given orally to prevent or treat organ transplant rejection. Tacrolimus has a narrow therapeutic index, and even minor differences in blood levels have the potential to cause graft rejection reactions</p>\n\n<h3>Oral tacrolimus and inadvertent switching between products</h3>\n\n<p>Since 2008, the MHRA has been aware of reports of unintended switching between different pharmaceutical forms of oral tacrolimus products in patients who have been treated with tacrolimus for the prevention of organ transplant rejection. Graft rejection reactions and tacrolimus toxicity have resulted from a small number of these unintended switches between products.</p>\n\n<h3>Prescribing oral tacrolimus products</h3>\n\n<p>As there are a growing number of tacrolimus products available on the UK market, the Commission on Human Medicines CHM has now advised that the risk of inadvertent switching between the different products may increase.</p>\n\n<p>Therefore, as a precautionary measure, the CHM has updated its advice on the safer use of oral tacrolimus products and recommends that <strong>all oral tacrolimus products should be prescribed and dispensed by brand name only</strong>. This supersedes previous advice regarding the prescribing, dispensing and interchangeability of different tacrolimus products (see Drug Safety Update January 2009, February 2010, and May 2010).</p>\n\n<p>A <a target=\"_blank\" href=\"https://www.cas.dh.gov.uk/ViewandAcknowledgment/ViewAlert.aspx?AlertID=101781\">letter on the updated advice for oral tacrolimus products</a> was sent to healthcare professionals in May 2012. The purpose of the new advice is to ensure maintenance of therapeutic response when a patient is stabilised on a particular brand, and to minimise the risk of inadvertent switching between products from different suppliers. As all tacrolimus products are approved in the UK with a brand name, the easiest way to achieve this is to prescribe by brand name only.</p>\n\n<p><strong>Important: careful therapeutic monitoring is recommended for any switching between tacrolimus brands. The currently available brands of oral tacrolimus are:</strong></p>\n\n<ul>\n<li>Immediate-release capsule taken twice daily (including Adoport, Aletris, Capexion, Evenil, Miloprosan, Prograf, Tacni, Takon, Taliximun, Tamitect and Vivadex)</li>\n\n<li>Prolonged-release capsule taken once daily (Advagraf)</li>\n\n<li>Granules for oral solution taken twice daily (Modigraf)</li>\n</ul>\n\n<p>If the exact brand of tacrolimus is not clearly stated on the prescription, the dispensing pharmacist should check with the prescriber to ensure that the appropriate medicine is dispensed.</p>\n\n<h3>Changing oral tacrolimus products</h3>\n\n<p>This updated recommendation does not preclude patients changing to a different tacrolimus brand if the prescriber considers this to be of benefit to the patient. However, changes between different brands (which may or may not involve changes in dosing regimen), should always be accompanied by careful therapeutic monitoring under the supervision of an appropriate specialist.</p>\n\n<div class=\"dull_highlight\">\n<p><strong>Advice for healthcare professionals and patients:</strong></p>\n\n<ul>\n<li>Prescribers should prescribe oral tacrolimus products by brand name only. When prescriptions have been previously written using the generic name, the brand on which the patient is stabilised should be established to ensure that the patient is supplied with the same product</li>\n</ul>\n\n<ul>\n<li>If a prescriber intends to switch between any tacrolimus brand, careful medical supervision and therapeutic monitoring are required</li>\n</ul>\n\n<ul>\n<li>Pharmacists should always dispense the exact brand prescribed. They should contact the prescriber if the prescription is not clear to ensure the appropriate medicine is dispensed</li>\n</ul>\n\n<ul>\n<li>Patients should be advised to take careful note of the brand name of their usual tacrolimus medicine and should check with their doctor or pharmacist if they receive a different brand or if they have any other questions about the prescription, eg about the dose</li>\n</ul>\n</div>\n\n<p><strong>Further information:</strong></p>\n\n<p><a target=\"_blank\" href=\"https://www.cas.dh.gov.uk/ViewandAcknowledgment/ViewAlert.aspx?AlertID=101781\">Letter to healthcare professionals on updated advice for oral tacrolimus products</a></p>\n\n<p><a target=\"_blank\" href=\"http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/CON152758\">MHRA information webpage on prescribing and dispensing oral tacrolimus products</a></p>\n\n<p>BNF section 8.2 <a target=\"_blank\" href=\"http://www.medicinescomplete.com/mc/bnf/current/27585.htm\">Drugs affecting the immune response</a></p>\n\n<p><em>Article citation: Drug Safety Update June 2012, vol 5 issue 11: A1</em></p>\r\n\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_END_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t", 
  "date_of_article": "2012-06-01", 
  "date_last_modified": "2012-06-21", 
  "_assets": [], 
  "_item_id": 112, 
  "summary": "The growing number of oral tacrolimus products available on the market increases the potential for inadvertent switching between products, which has been associated with reports of toxicity and graft rejection. Therefore, to ensure maintenance of therapeutic response when a patient is stabilised on a particular brand, oral tacrolimus products should be prescribed and dispensed by brand name only.\n\nIf a prescriber considers that switching a patient to a different brand of oral tacrolimus would be of benefit, the change requires careful supervision and therapeutic monitoring by an appropriate specialist", 
  "body": "Article date: June 2012\n\nTacrolimus is an immunosuppressant drug which may be given orally to prevent or treat organ transplant rejection. Tacrolimus has a narrow therapeutic index, and even minor differences in blood levels have the potential to cause graft rejection reactions\n\n### Oral tacrolimus and inadvertent switching between products\n\nSince 2008, the MHRA has been aware of reports of unintended switching between different pharmaceutical forms of oral tacrolimus products in patients who have been treated with tacrolimus for the prevention of organ transplant rejection. Graft rejection reactions and tacrolimus toxicity have resulted from a small number of these unintended switches between products.\n\n### Prescribing oral tacrolimus products\n\nAs there are a growing number of tacrolimus products available on the UK market, the Commission on Human Medicines CHM has now advised that the risk of inadvertent switching between the different products may increase.\n\nTherefore, as a precautionary measure, the CHM has updated its advice on the safer use of oral tacrolimus products and recommends that all oral tacrolimus products should be prescribed and dispensed by brand name only. This supersedes previous advice regarding the prescribing, dispensing and interchangeability of different tacrolimus products (see Drug Safety Update January 2009, February 2010, and May 2010).\n\nA [letter on the updated advice for oral tacrolimus products](https://www.cas.dh.gov.uk/ViewandAcknowledgment/ViewAlert.aspx?AlertID=101781) was sent to healthcare professionals in May 2012. The purpose of the new advice is to ensure maintenance of therapeutic response when a patient is stabilised on a particular brand, and to minimise the risk of inadvertent switching between products from different suppliers. As all tacrolimus products are approved in the UK with a brand name, the easiest way to achieve this is to prescribe by brand name only.\n\nImportant: careful therapeutic monitoring is recommended for any switching between tacrolimus brands. The currently available brands of oral tacrolimus are:  \n  \n  * Immediate-release capsule taken twice daily (including Adoport, Aletris, Capexion, Evenil, Miloprosan, Prograf, Tacni, Takon, Taliximun, Tamitect and Vivadex)  \n  * Prolonged-release capsule taken once daily (Advagraf)  \n  * Granules for oral solution taken twice daily (Modigraf)  \n  \nIf the exact brand of tacrolimus is not clearly stated on the prescription, the dispensing pharmacist should check with the prescriber to ensure that the appropriate medicine is dispensed.\n\n### Changing oral tacrolimus products\n\nThis updated recommendation does not preclude patients changing to a different tacrolimus brand if the prescriber considers this to be of benefit to the patient. However, changes between different brands (which may or may not involve changes in dosing regimen), should always be accompanied by careful therapeutic monitoring under the supervision of an appropriate specialist.\n\nAdvice for healthcare professionals and patients:  \n  \n  * Prescribers should prescribe oral tacrolimus products by brand name only. When prescriptions have been previously written using the generic name, the brand on which the patient is stabilised should be established to ensure that the patient is supplied with the same product  \n  * If a prescriber intends to switch between any tacrolimus brand, careful medical supervision and therapeutic monitoring are required  \n  * Pharmacists should always dispense the exact brand prescribed. They should contact the prescriber if the prescription is not clear to ensure the appropriate medicine is dispensed  \n  * Patients should be advised to take careful note of the brand name of their usual tacrolimus medicine and should check with their doctor or pharmacist if they receive a different brand or if they have any other questions about the prescription, eg about the dose  \n  \nFurther information:\n\n[Letter to healthcare professionals on updated advice for oral tacrolimus products](https://www.cas.dh.gov.uk/ViewandAcknowledgment/ViewAlert.aspx?AlertID=101781)\n\n[MHRA information webpage on prescribing and dispensing oral tacrolimus products](http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/CON152758)\n\nBNF section 8.2 [Drugs affecting the immune response](http://www.medicinescomplete.com/mc/bnf/current/27585.htm)\n\nArticle citation: Drug Safety Update June 2012, vol 5 issue 11: A1\n"
}